Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Cell Reports|July 2, 2020
Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a ChaperonePengrong Yan, Hardik J Patel, Sahil Sharma, et al.
Lancet (London, England)|December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyChiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
European Heart Journal|February 22, 2023
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trialJessica M Scott, Jasme Lee, James E Herndon, et al.
Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.
Cancer Discovery|July 16, 2021
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent PembrolizumabPrasad S Adusumilli, Marjorie G Zauderer, Isabelle Rivière, et al.
Nature Communications|June 23, 2023
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptationAnna Rodina, Chao Xu, Chander S Digwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur, Hope Rugo, Benjamin Nulsen, et al.
Research Square|April 22, 2024
Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and ProliferationSeth W McNutt, Tanaya Roychowdhury, Chiranjeevi Pasala, et al.
Cancer Cell|November 1, 2019
Paradigms for Precision Medicine in Epichaperome Cancer TherapyNagavarakishore Pillarsetty, Komal Jhaveri, Tony Taldone, et al.
Nature Communications|October 16, 2024
Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferationTanaya Roychowdhury, Seth W McNutt, Chiranjeevi Pasala, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Cell Reports|July 2, 2020
Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a ChaperonePengrong Yan, Hardik J Patel, Sahil Sharma, et al.
Lancet (London, England)|December 17, 2023
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyChiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian, et al.
European Heart Journal|February 22, 2023
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trialJessica M Scott, Jasme Lee, James E Herndon, et al.
Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.
Cancer Discovery|July 16, 2021
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent PembrolizumabPrasad S Adusumilli, Marjorie G Zauderer, Isabelle Rivière, et al.
Nature Communications|June 23, 2023
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptationAnna Rodina, Chao Xu, Chander S Digwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur, Hope Rugo, Benjamin Nulsen, et al.
Research Square|April 22, 2024
Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and ProliferationSeth W McNutt, Tanaya Roychowdhury, Chiranjeevi Pasala, et al.
Cancer Cell|November 1, 2019
Paradigms for Precision Medicine in Epichaperome Cancer TherapyNagavarakishore Pillarsetty, Komal Jhaveri, Tony Taldone, et al.
Nature Communications|October 16, 2024
Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferationTanaya Roychowdhury, Seth W McNutt, Chiranjeevi Pasala, et al.
Pageof 12